Clinical trial · Observational
An External Control Arm Study in Non-Small Cell Lung Cancer
A Prospective Study to Generate Precision External Controls in Advanced or Metastatic Non Small Cell Lung Cancer Patients
NCT07174388CI-TRIAL-00121125recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
A study to create control arms using current and future information in patients with lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (11)
- label
- Cohort 1
- description
- Patients starting first line therapy with ICI single/doublet or ICI in combination with a platinum doublet
- label
- Cohort 2
- description
- Patients with actionable EGFR mutations starting first line therapy
- label
- Cohort 3
- description
- Patients with KRAS G12D mutations (excluding KRAS G12C) starting any line of therapy
- label
- Cohort 4
- description
- Patients with PD-L1 (TPS) greater than or equal to 50% starting second line therapy, after previously being treated with single/doublet ICI or ICI in combination with a platinum doublet as first line treatment.
- label
- Cohort 5
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. \> 18 years of age at the time of informed consent 2. Pathologically confirmed locally advanced or metastatic NSCLC 3. ECOG Performance of less than or equal to 1 within 4 weeks prior to starting index therapy. 4. Life expectancy of more than 3 months 5. Able to understand and sign informed consent 6. Evidence of measurable disease (as assessed by the Investigator) on available imaging (e.g CT, MRI, PET) \*see protocol for cohort specific inclusion criteria\* Exclusion Criteria: 1. Actively on a clinical trial of an investigational agent 2. Currently receiving active systemic therapy for another malignancy 3. Eligible for treatment with curative intent \*see protocol for cohort specific exclusion criteria\*
References
Publications (0)
Data not yet available
No reference posted for this study.